ProQR Therapeutics N.V. - ADR

Name: ProQR Therapeutics N.V. - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: ProQR Therapeutics N.V. - ADR

Stock Card

$2.31

$-0.02 (-0.65%)

As on 28-Aug-2026 13:36EDT

Market cap

$330 Mln

Revenue (TTM)

$19 Mln

P/E Ratio

P/B Ratio

3.5

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

ProQR Therapeutics N.V. - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.28 High: 2.35

52 Week Range

Low: 1.33 High: 3.10

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.6 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-2.1
Debt to Equity

0
Book Value

$--
EPS

$-0.4
Face value

--
Shares outstanding

141,119,032

10 Years Aggregate

CFO

€-302.99 Mln

EBITDA

€-421.80 Mln

Net Profit

€-410.07 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
ProQR Therapeutics N.V. - ADR	14.1	33.2	47.8	4.3	14.1	-18.8	-8.5
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
ProQR Therapeutics N.V. - ADR	-23.8	-46.5	-53.8	90.7	-57.6	-37.2
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About ProQR Therapeutics N.V. - ADR

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders... with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Read more

Founder & Independent Chairman of Supervisory Board

Dr. Domenico Valerio Ph.D.
Founder & Independent Chairman of Supervisory Board

Dr. Domenico Valerio Ph.D.
Headquarters

Leiden
Website

https://www.proqr.com

FAQs for ProQR Therapeutics N.V. - ADR

What is the current share price of ProQR Therapeutics NV - ADR Today?

The share price of ProQR Therapeutics NV - ADR is $2.31 (NASDAQ) as of 28-Aug-2026 13:36 EDT. ProQR Therapeutics NV - ADR has given a return of 14.14% in the last 3 years.

What is the current PB & PE ratio of ProQR Therapeutics NV - ADR?

Since, TTM earnings of ProQR Therapeutics NV - ADR is negative, P/E ratio is not available.
The P/B ratio of ProQR Therapeutics NV - ADR is 3.48 times as on 21-Aug-2026, a 0 premium to its peers’ median range of 3.48 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-5.14	3.59
2024	-7.80	2.36
2023	-5.52	3.40
2022	-4.44	4.00
2021	-9.39	4.41

What is the 52 Week High and Low of ProQR Therapeutics NV - ADR?

The 52-week high and low of ProQR Therapeutics NV - ADR are Rs 3.10 and Rs 1.33 as of 29-Aug-2026.

What is the market cap of ProQR Therapeutics NV - ADR?

ProQR Therapeutics NV - ADR has a market capitalisation of $ 330 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in ProQR Therapeutics NV - ADR?

Before investing in ProQR Therapeutics NV - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.